Defendant
2 cases as defendant.
Cadila Healthcare Ltd. — now Zydus Lifesciences Limited (commonly "Zydus Cadila") — is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat. The Zydus group traces its founding to 1952; Cadila Healthcare was incorporated in 1995 and renamed Zydus Lifesciences effective February 2022. It is publicly listed on the BSE (532321) and NSE (ZYDUSLIFE) and is controlled by the Zydus Family Trust. Wikipedia and investor materials cite FY2025 revenue of roughly ₹23,241 crore (~US$2.4–2.7 billion) and a workforce of about 25,000–28,000. (Sources: Wikipedia; zyduslife.com investor filings; Investing.com company profile.)
Operations. Zydus is a fully integrated life-sciences group spanning generics, branded formulations, biosimilars, vaccines, active pharmaceutical ingredients (APIs), animal health, and consumer wellness brands (e.g., Complan, Glucon-D, Everyuth, Nutralite, Nycil). It reports operations in roughly 55 countries with 30-plus manufacturing plants, and its US generics arm, Zydus Pharmaceuticals (USA) Inc., markets several hundred SKUs of unbranded generics and files ANDAs and drug master files with the FDA. (Sources: Zydus press releases; Pharmacy Times company profile.)
Litigation posture. This is an operating company, not an NPE or shell licensor. The tracked data show one case, with Cadila as a defendant and none as plaintiff — consistent with a generic manufacturer defending Hatch-Waxman patent challenges filed by brand owners. The single case sits in the District of Delaware, a common venue for ANDA litigation, not a plaintiff-friendly NPE venue.
Notable case. Merck Sharp & Dohme Corp. v. Zydus Pharmaceuticals (USA) Inc. et al., No. 1:19-cv-00314 (D. Del., filed Feb. 13, 2019), named Zydus Pharmaceuticals and parent Cadila Healthcare as defendants. It concerned sitagliptin phosphate — the active ingredient in Merck's Januvia/Janumet diabetes products — and was folded into MDL No. 2902, In re Sitagliptin Phosphate ('708 & '921) Patent Litigation. The case was dismissed without prejudice as to Zydus and Cadila in September 2021. (Sources: Justia Dockets; CourtListener; JPML transfer order.)
No litigation-funding or parent-ownership issues apply; Cadila is the ultimate parent of the US subsidiary named in the suit.
Settled Dec. 2022; dismissal without prejudice permitted Zydus to seek approval of a non-automatically substitutable product with a different sitagliptin form.
Celgene sued Zydus/Cadila/Zydus International for patent infringement under 35 U.S.C. § 271(e)(2) in D.N.J. The case asserted multiple lenalidomide patents including 8,648,095. Consent judgment entered 2021-03-24 dismissing with prejudice pursuant to settlement.